PDF(Pubmed)
Abstract：
BACKGROUND: Osteoporotic vertebral compression fractures (OVCFs) contribute to back pain and functional limitations in older individuals, with percutaneous vertebroplasty (PVP) emerging as a minimally invasive treatment. However, further height loss post-PVP prompts investigation into contributing factors.
OBJECTIVE: To investigate the factors associated with further height loss following PVP with cement augmentation in OVCF patients.
METHODS: A total of 200 OVCF patients who underwent successful PVP between January 2021 and December 2022 were included in this study. \"Further height loss\" during 1 year of follow-up in OVCF patients with bone edema was defined as a vertical height loss of ≥ 4 mm. The study population was divided into two groups for analysis: The \"No Further Height Loss group (n = 179)\" and the \"Further Height Loss group (n = 21).\"
RESULTS: In comparing two distinct groups of patients, significant differences existed in bone mineral density (BMD), vertebral compression degree, prevalence of intravertebral cleft (IVF), type of bone cement used, and cement distribution patterns. Results from binary univariate regression analysis revealed that lower BMD, the presence of IVF, cleft distribution of bone cement, and higher vertebral compression degree were all significantly associated with further height loss. Notably, the use of mineralized collagen modified-poly(methyl methacrylate) bone cement was associated with a significant reduction in the risk of further height loss. In multivariate regression analysis, lower BMD and the presence of IVF remained significantly associated with further height loss.
CONCLUSIONS: Further height loss following PVP in OVCF patients is influenced by a complex interplay of factors, especially lower BMD and the presence of IVF. These findings underscore the importance of assessing and managing these factors when addressing height loss following PVP in OVCF patients.
OBJECTIVE: To investigate the factors associated with further height loss following PVP with cement augmentation in OVCF patients.
METHODS: A total of 200 OVCF patients who underwent successful PVP between January 2021 and December 2022 were included in this study. \"Further height loss\" during 1 year of follow-up in OVCF patients with bone edema was defined as a vertical height loss of ≥ 4 mm. The study population was divided into two groups for analysis: The \"No Further Height Loss group (n = 179)\" and the \"Further Height Loss group (n = 21).\"
RESULTS: In comparing two distinct groups of patients, significant differences existed in bone mineral density (BMD), vertebral compression degree, prevalence of intravertebral cleft (IVF), type of bone cement used, and cement distribution patterns. Results from binary univariate regression analysis revealed that lower BMD, the presence of IVF, cleft distribution of bone cement, and higher vertebral compression degree were all significantly associated with further height loss. Notably, the use of mineralized collagen modified-poly(methyl methacrylate) bone cement was associated with a significant reduction in the risk of further height loss. In multivariate regression analysis, lower BMD and the presence of IVF remained significantly associated with further height loss.
CONCLUSIONS: Further height loss following PVP in OVCF patients is influenced by a complex interplay of factors, especially lower BMD and the presence of IVF. These findings underscore the importance of assessing and managing these factors when addressing height loss following PVP in OVCF patients.
摘要：
背景：骨质疏松性椎体压缩性骨折（OVCF）导致老年人背痛和功能受限，经皮椎体成形术（PVP）成为一种微创治疗方法。然而,PVP后进一步的身高下降提示对影响因素进行调查.
目的：探讨OVCF患者PVP合并骨水泥强化后身高进一步下降的相关因素。
方法：本研究纳入了在2021年1月至2022年12月期间成功进行PVP的200例OVCF患者。对骨水肿的OVCF患者进行1年随访期间的“进一步高度下降”定义为垂直高度下降≥4mm。将研究人群分为两组进行分析：“无进一步身高损失组（n=179）”和“进一步身高损失组（n=21）”。\"
结果：在比较两组不同的患者时，骨密度(BMD)存在显著差异，椎体压缩程度,椎间隙（IVF）的患病率，使用的骨水泥类型，和水泥分布模式。二元单变量回归分析的结果表明，较低的BMD，试管婴儿的存在，骨水泥的裂缝分布，和更高的椎体压缩程度都与进一步的高度损失显着相关。值得注意的是,矿化胶原改性聚(甲基丙烯酸甲酯)骨水泥的使用与进一步身高下降的风险显著降低相关.在多元回归分析中，较低的BMD和IVF的存在仍然与进一步的身高损失显著相关.
结论：OVCF患者PVP后进一步的身高下降受多种因素相互作用的影响，尤其是较低的BMD和IVF的存在。这些发现强调了在解决OVCF患者PVP后身高下降时评估和管理这些因素的重要性。
目的：探讨OVCF患者PVP合并骨水泥强化后身高进一步下降的相关因素。
方法：本研究纳入了在2021年1月至2022年12月期间成功进行PVP的200例OVCF患者。对骨水肿的OVCF患者进行1年随访期间的“进一步高度下降”定义为垂直高度下降≥4mm。将研究人群分为两组进行分析：“无进一步身高损失组（n=179）”和“进一步身高损失组（n=21）”。\"
结果：在比较两组不同的患者时，骨密度(BMD)存在显著差异，椎体压缩程度,椎间隙（IVF）的患病率，使用的骨水泥类型，和水泥分布模式。二元单变量回归分析的结果表明，较低的BMD，试管婴儿的存在，骨水泥的裂缝分布，和更高的椎体压缩程度都与进一步的高度损失显着相关。值得注意的是,矿化胶原改性聚(甲基丙烯酸甲酯)骨水泥的使用与进一步身高下降的风险显著降低相关.在多元回归分析中，较低的BMD和IVF的存在仍然与进一步的身高损失显著相关.
结论：OVCF患者PVP后进一步的身高下降受多种因素相互作用的影响，尤其是较低的BMD和IVF的存在。这些发现强调了在解决OVCF患者PVP后身高下降时评估和管理这些因素的重要性。
